Skip to NavigationSkip to content


AZ licenses kidney drug from Ionis for $330m

AstraZeneca continues to build on its relationship with San Diego-based Ionis Pharmaceuticals, this time by agreeing a licensing deal for a drug to be developed for the treatment of kidney disease.

The press release on the announcement did not divulge many details on what the target area actually is, only specifying that it was a designed to target a genetically associated form of kidney disease.

The candidate that AZ is forking out to license is IONIS-AZ5-2.5RX – with the 2.5 relating to the drug being a “Generation 2.5 antisense drug”.

Keryx Biopharmaceuticals announces positive Phase III study results for anaemia treatment

Keryx Biopharmaceuticals (NASDAQ: KERX) has announced positive top-line results for its Phase III study of ferric citrate for the treatment of iron deficiency anaemia (IDA) in adults with non-dialysis dependent chronic kidney disease.

Novel device could help fight kidney disease

QELFA device
Creators of the £10 QELFA gadget are hoping to enter the kidney disease market

A novel device that combines nanotechnology and a pregnancy tester could help treat kidney disease, according to a report by the Institution of Mechanical Engineers (IME).

The quantitative electrochemical lateral flow assay (QELFA) tool has been developed by engineers at London-based firm Bio Nano Consulting – jointly owned by Imperial College London and University College London – and uses nanoparticles to test the patient’s ur

Research pact joins Pfizer and Merck Serono with academics

Merck Serono image

Merck’s US affiliate EMD Serono and Pfizer have entered into a research agreement with the Broad Institute to investigate autoimmune disease treatment avenues.

Specifically the collaboration is to focus on the genomic profiling of Systemic Lupus Erythematosus (SLE) and Lupus Nephritis (LN) patients, and will be funded by Merck Serono (the biopharma division of Merck) and Pfizer.

Novartis signs Regenerex deal

Novartis image

Novartis has signed a deal with US biopharma firm Regenerex to use its novel stem cell-based platform, which may have a key application in helping kidney transplant patients.

The Kentucky-based firm’s novel Facilitating Cell Therapy (FCRx) platform is the subject of the global licensing and research collaboration, which will see Novartis examine its potential benefit in a variety of areas.

Transplant patients currently have to take immunosuppressive drugs for life to prevent the body from rejecting the donated organ.

AstraZeneca signs $350m kidney deal

astrazeneca image

AstraZeneca has signed a deal with private biotech company FibroGen to develop a novel compound aimed at treating anaemia associated with chronic kidney disease (CKD) and end-stage renal disease (ESRD).

The Anglo-Swedish group will pay $350 million upfront plus milestones of up to $465 million, with tiered royalty payments on future sales ‘in the low 20% range’.

Abbott pulls kidney disease trial

Abbott image

Abbott has terminated its Phase III trial of bardoxolone methyl in patients with kidney disease and diabetes after concerns over adverse events and deaths.

The BEACON trial, run with Texas-based Reata Pharmaceuticals, which discovered the drug, was looking at its performance in patients with stage 4 chronic kidney disease (CKD) and type II diabetes versus placebo.

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches